CLINICAL Cell Culture is heading to the UK, setting up a corporate office in Cambridge.
Giving the relocation plan a boost is news that the British Medicines and Healthcare products Regulator Agency has authorised the supply of C3’s CellSpray and CellSpray XP.
C3 CEO Troels Jordansen said the authorisation was an important step for the company and a milestone in its plan for product commercialisation in Europe.
He said the UK was a strong potential market for the company’s products.
“The authorisation recognises the secure and innovative nature of our products. Although procedures are well established in the UK, cultured skin is mainly supplied through a limited number of hospital laboratories satisfying their own local needs,” Mr Jordansen said.
C3 will remain listed on the Australian Stock Exchange and have a majority of Australian-based directors. Its research and development activities will also remain here.